Format

Send to

Choose Destination
See comment in PubMed Commons below
ACS Chem Neurosci. 2011 Aug 17;2(8):402-10. doi: 10.1021/cn200019z. Epub 2011 Mar 22.

Fragile X syndrome: an update on developing treatment modalities.

Author information

1
Seaside Therapeutics, 840 Memorial Drive, Cambridge, Masssachusetts 02139, USA.

Abstract

Intellectual disability (ID; mental retardation) is considered an immutable condition. Current medical practices are aimed at relieving symptoms and not at altering the underlying cognitive deficits. Scientific advancements from the past decade have led to the exciting possibility that ID may now be treatable. Moreover, pharmaceutical therapies targeting the most common form of inherited ID, Fragile X syndrome (FXS), may become the new benchmark for central nervous system (CNS) drug discovery: seeking cures for neurodevelopmental disorders.

KEYWORDS:

Fragile X syndrome; fragile X mental retardation gene; fragile X mental retardation protein; metabotropic glutamate receptor 5; γ-aminobutyric acid

PMID:
22860169
PMCID:
PMC3369755
DOI:
10.1021/cn200019z
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for American Chemical Society Icon for PubMed Central
    Loading ...
    Support Center